For laboratory research use only. Not for human or veterinary use. Read our research-use policy

Peptide profile

CagriSema: cagrilintide plus semaglutide

CagriSema is a pairing of two peptides that act on different hormone systems. This page describes each molecule, the pharmacology and the structure of the published trial programme. It reports study designs, not outcomes in people.

Published 18 November 2026 · Last updated 18 November 2026

The two molecules

Cagrilintide and semaglutide compared
CagrilintideSemaglutide
ClassLong-acting, lipidated amylin analogueLong-acting GLP-1 receptor agonist (GLP-1 analogue)
Natural counterpartAmylin, a pancreatic hormone that induces satietyGlucagon-like peptide-1
Formula (PubChem)C194H312N54O59S2, about 4409 g/molC187H291N45O59, about 4114 g/mol
Average mass from the formula4409.1 Da4113.6 Da
ReceptorsAmylin and calcitonin receptorsGLP-1 receptor
Key papersKruse et al., 2021 (J Med Chem); Lau et al., 2021 (Lancet)Lau et al., 2015 (J Med Chem)

Kruse et al. (2021) describe cagrilintide as a stable, lipidated, long-acting amylin analogue developed after structure-activity work, noting that amylin itself readily forms amyloid fibrils, which makes drug design hard, and that the earlier analogue pramlintide has a short half-life. Carvas et al. (2025) report in mice that cagrilintide's effect on body weight depends on the amylin 1 and 3 receptors (AMY1R and AMY3R, built from the calcitonin receptor and RAMP1 or RAMP3): in RAMP1/3 knockout mice its potency was reduced. See the compound pages for cagrilintide and semaglutide.

How the research programme is structured

  1. Phase 2 for cagrilintide alone. Lau et al. (2021) ran a 26-week dose-finding trial at 57 sites in ten countries, with 706 participants assigned to cagrilintide, 99 to liraglutide and 101 to placebo.
  2. Phase 1b for the combination. Enebo et al. (2021) ran a randomised, placebo-controlled, multiple-ascending-dose trial of cagrilintide with semaglutide at a fixed dose in 96 randomised participants across six cohorts. They report half-lives of 159 to 195 hours for cagrilintide and 145 to 165 hours for semaglutide, similar clearance and volume of distribution across groups, and an acceptable safety profile.
  3. Phase 3 REDEFINE. REDEFINE 1 (Garvey et al., 2025) was a 68-week, double-blind trial in adults without diabetes with 3417 participants randomised to the combination, each component alone, or placebo. REDEFINE 2 (Davies et al., 2025) was a 68-week, double-blind, placebo-controlled trial in 1206 adults with obesity and type 2 diabetes. REDEFINE 3, the cardiovascular outcomes trial, has a published design and baseline-characteristics paper (Cavender et al., 2026). REDEFINE 9 (Wharton et al., 2026) is a phase 3b trial of two lower dose levels against placebo.

The primary endpoints of the phase 3 papers are body-weight outcomes, and the papers report adverse events including gastrointestinal events. Read the primary papers for results; this page does not summarise them as claims.

Why people compare the two molecules

Because the two act through different receptor systems, a combination makes it possible to study their effects together and apart: the REDEFINE 1 design includes each component alone for exactly that comparison. This is a design feature of the trials rather than a conclusion.

Identity and analytical notes

Both peptides are large enough that their mass spectra show a series of multiply charged ions rather than a single [M+H]+. For cagrilintide the 4+, 5+ and 6+ ions are expected near 1103.3, 882.8 and 735.9; for semaglutide near 1029.4, 823.7 and 686.6. For a vial that contains both, expect both series. Checking the mass spectrometry on a COA yourself explains the calculation. The calculator's blend mode handles the arithmetic of a two-compound vial.

Catalog

Related

References

  1. Kruse T, Hansen JL, Dahl K, et al. (2021). Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem 64:11183-11194. PubMed 34288673 · DOI
  2. Lau J, Bloch P, Schäffer L, et al. (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem 58:7370-80. PubMed 26308095 · DOI
  3. Lau DCW, Erichsen L, Francisco AM, et al. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet 398:2160-2172. PubMed 34798060 · DOI
  4. Enebo LB, Berthelsen KK, Kankam M, et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet 397:1736-1748. PubMed 33894838 · DOI
  5. Garvey WT, Blüher M, Osorto Contreras CK, et al. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med 393:635-647. PubMed 40544433 · DOI
  6. Davies MJ, Bajaj HS, Broholm C, et al. (2025). Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med 393:648-659. PubMed 40544432 · DOI
  7. Cavender MA, Jastreboff AM, Cheng AYY, et al. (2026). Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3). Am Heart J 304:107626. PubMed 42838477 · DOI
  8. Wharton S, Broholm C, Horn D, et al. (2026). Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial. Lancet Diabetes Endocrinol. PubMed 43033821 · DOI
  9. Carvas AO, Leuthardt A, Kulka P, et al. (2025). Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. EBioMedicine 118:105836. PubMed 40609154 · DOI

Frequently asked questions

What is CagriSema?

CagriSema is the name for the combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist. The phase 3 papers describe the two being co-administered.

How do cagrilintide and semaglutide differ?

Cagrilintide is an amylin analogue (about 4409 g/mol) acting at amylin and calcitonin receptors. Semaglutide is a GLP-1 analogue (about 4114 g/mol). They act on different receptor systems.

What is the REDEFINE programme?

REDEFINE is the phase 3 trial programme for cagrilintide-semaglutide. Published reports include REDEFINE 1 (adults with overweight or obesity, 3417 randomised, 68 weeks), REDEFINE 2 (adults with obesity and type 2 diabetes, 1206 randomised, 68 weeks), REDEFINE 3 (cardiovascular outcomes design paper) and REDEFINE 9 (phase 3b, other dose levels).